Abiomed's Stock Gains Following Positive Q3, Revised Guidance

Shares of ABIOMED, Inc.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

(NASDAQ: ABMD) were trading higher by 4 percent early Thursday morning after the company reported its third quarter results.Abiomed said that it earned $0.23 per share in the third quarter on revenue of $85.79 million. Wall Street analysts were expecting the company to earn $0.15 per share on revenue of $80 million.Income from operations rose to $17.5 million during the quarter from $13.7 million a year ago. The company noted that the installed base for its Impella 2.5 heart pumps grew by an additional 20 hospitals, bringing its total count to 1,020 sites. In addition, 49 new hospitals purchased Impella CP, bringing the total number to 788 sites with Impella CP heart pumps.Looking forward to the full fiscal year, Abiomed raised its sales outlook from $305 million to $315 million to $326 million - exceeding the $314.7 million Wall Street analysts were expecting."I am proud of our discipline and execution that we have demonstrated in achieving this early phase of success. We are operationally prepared with our sector expertise to take advantage of this unique organic opportunity," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "Abiomed is revolutionizing the treatment for heart failure by focusing exclusively on the heart muscle and with new indications, new geographies and new products on the horizon; the Impella platform has a long runway for growth."